Daxor Corporation (DXR) P/E Ratio History
UndervaluedTrading at 5.5x vs 5Y avg 22.1x · 30th percentile · Below historical baseline · Data 1989–2025
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, Daxor Corporation (DXR) trades at a price-to-earnings ratio of 5.5x, with a stock price of $10.11 and trailing twelve-month earnings per share of $1.92.
The current P/E is 75% below its 5-year average of 22.1x. Over the past five years, DXR's P/E has ranged from a low of 1.3x to a high of 135.0x, placing the current valuation at the 30th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, DXR trades at a 76% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, DXR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DXR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DXR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
DXR P/E vs Peers
Diagnostics and life science tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $17B | 30.5 | - | -25% | |
| $56B | 26.6 | 1.61Best | -1% | |
| $144B | 51.6 | 2.37 | +23%Best | |
| $161B | 24.9 | 3.01 | -51% | |
| $104B | 21.7Lowest | 3.10 | +3% | |
| $127B | 39.3 | 2.65 | +8% | |
| $18B | 25.7 | - | -20% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
DXR Historical P/E Data (1989–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $14.75 | $1.92 | 7.7x | -92% |
| FY2025 Q2 | Jun 30 2025 | $9.79 | $0.75 | 13.1x | -86% |
| FY2024 Q4 | - | $7.69 | $0.36 | 21.4x | -78% |
| FY2024 Q2 | Jun 30 2024 | $9.32 | $0.73 | 12.8x | -87% |
| FY2023 Q4 | Dec 31 2023 | $9.60 | $0.85 | 11.3x | -88% |
| FY2023 Q2 | Jun 30 2023 | $9.60 | $0.91 | 10.5x | -89% |
| FY2022 Q4 | Dec 31 2022 | $9.16 | $1.18 | 7.8x | -92% |
| FY2022 Q2 | - | $13.20 | $0.60 | 22.0x | -77% |
| FY2017 Q4 | Dec 31 2017 | $4.57 | $0.04 | 112.9x | +19% |
| FY2012 Q4 | Dec 31 2012 | $7.60 | $0.15 | 50.7x | -47% |
| FY2011 Q2 | - | $10.18 | $1.32 | 7.7x | -92% |
| FY2010 Q4 | Dec 31 2010 | $9.25 | $3.17 | 2.9x | -97% |
| FY2010 Q2 | Jun 30 2010 | $10.06 | $4.94 | 2.0x | -98% |
| FY2009 Q4 | - | $12.05 | $8.21 | 1.5x | -98% |
| FY2009 Q2 | - | $10.30 | $8.10 | 1.3x | -99% |
| FY2008 Q4 | Dec 31 2008 | $15.40 | $8.43 | 1.8x | -98% |
| FY2008 Q2 | Jun 30 2008 | $15.85 | $5.33 | 3.0x | -97% |
| FY2007 Q4 | Dec 31 2007 | $14.63 | $2.05 | 7.1x | -93% |
| FY2007 Q2 | Jun 30 2007 | $15.25 | $1.59 | 9.6x | -90% |
| FY2006 Q4 | Dec 31 2006 | $14.85 | $0.11 | 135.0x | +42% |
| FY2006 Q2 | Jun 30 2006 | $17.16 | $0.25 | 68.8x | -28% |
| FY2005 Q4 | Dec 31 2005 | $17.26 | $0.15 | 111.9x | +17% |
| FY2002 Q4 | - | $14.80 | $0.02 | 654.9x | +587% |
| FY2002 Q2 | Jun 30 2002 | $17.74 | $0.04 | 473.1x | +397% |
| FY2001 Q4 | Dec 31 2001 | $19.59 | $0.05 | 373.9x | +292% |
| FY2001 Q2 | Jun 30 2001 | $15.75 | $0.01 | 1485.8x | +1460% |
| FY1997 Q2 | Jun 30 1997 | $8.56 | $0.09 | 95.1x | -0% |
| FY1996 Q4 | - | $13.75 | $0.24 | 57.3x | -40% |
| FY1996 Q2 | Jun 30 1996 | $13.25 | $0.37 | 35.8x | -62% |
| FY1995 Q4 | Dec 31 1995 | $6.88 | $0.61 | 11.3x | -88% |
| FY1995 Q2 | Jun 30 1995 | $6.88 | $0.66 | 10.4x | -89% |
| FY1994 Q4 | Dec 31 1994 | $5.75 | $0.75 | 7.7x | -92% |
| FY1994 Q2 | - | $6.50 | $0.94 | 6.9x | -93% |
| FY1993 Q4 | Dec 31 1993 | $5.88 | $1.06 | 5.5x | -94% |
| FY1993 Q2 | Jun 30 1993 | $6.50 | $0.72 | 9.0x | -91% |
| FY1992 Q4 | - | $7.25 | $0.69 | 10.5x | -89% |
| FY1992 Q2 | - | $8.50 | $0.71 | 12.0x | -87% |
| FY1991 Q4 | - | $2.75 | $0.32 | 8.5x | -91% |
| FY1990 Q4 | Dec 31 1990 | $2.50 | $0.52 | 4.8x | -95% |
| FY1990 Q2 | Jun 30 1990 | $3.25 | $0.48 | 6.7x | -93% |
| FY1989 Q4 | Dec 31 1989 | $3.00 | $0.22 | 13.8x | -86% |
Average P/E for displayed period: 95.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DXR — Frequently Asked Questions
Quick answers to the most common questions about buying DXR stock.
What is DXR's P/E ratio?
Daxor Corporation (DXR) trailing twelve-month P/E ratio is 5.5x, based on TTM diluted EPS of $1.92. The 5-year average P/E is 22.1x and the historical range spans 1.3x to 135.0x.
Is DXR stock overvalued or undervalued?
DXR trades at 5.5x P/E, below its 5-year average of 22.1x. At the 30th percentile of its historical range (1.3x–135.0x), the stock is priced at a discount to its own history.
Is DXR stock expensive?
No, DXR is not expensive on a historical basis. The current P/E of 5.5x is below the 5-year average of 22.1x and sits at the 30th percentile of its valuation range.
What is DXR's historical P/E range?
Over the past 5 years, DXR's P/E ratio has ranged from 1.3x to 135.0x, with a median of 9.6x and an average of 22.1x. The current P/E of 5.5x places the stock at the 30th percentile of this range. Full historical data spans 1989–2025.
How does DXR's P/E compare to the S&P 500?
DXR trades at 5.5x P/E versus the S&P 500 median of 25.1x. The 78% discount to the market suggests lower growth expectations or perceived higher risk.
How does DXR's valuation compare to Healthcare peers?
Daxor Corporation P/E of 5.5x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is DXR's PEG ratio?
DXR PEG ratio is N/A, based on a P/E of 5.5x and EPS growth of 1572.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is DXR's earnings yield?
DXR earnings yield is 18.20%, the inverse of its 5.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.